LtaS-IN-1 是多药耐药粪肠球菌中脂磷壁酸合成的有效抑制剂，可改变细胞壁形态。 LtaS-IN-1 对抗肠球菌属 28 菌株，MIC 值从 0.5 μg/mL 到 64 μg/mL 不等。 LtaS-IN-1 抑制菌株 E1630 和 E1590，MIC 值为 0.5 μg/mL。

LtaS-IN-1 is an effective inhibitor of Lipoteichoic acid synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 is against Enterococcus spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 inhibits strain E1630 and E1590 with MIC values of 0.5 μg/mL.

LtaS-IN-1 (20 μM) combines with either ampicillin (20 μg/mL), gentamicin (10 μg/mL), linezolid (5 μg/mL), daptomycin (10 μg/mL+50 μg/mL calcium chloride) or vancomycin (20 μg/mL) can inhibit strains E7128 and E7130 growth by 97-100%, while LtaS-IN-1 alone only gives 73% (strain E7128) and 8% (strain E7130) of growth inhibition, respectively. LtaS-IN-1 (0-100 μM) inhibits strain E745 growth as a concentration-dependent manner. LtaS-IN-1 (10 μM) leads to a 60% reduction in the final OD600 for this strain. Meanwhile, LtaS-IN-1 does not affect E. faecium growth in control group[1].

877950-01-1

C24H17N3O5

427.41

DMSO:120 mg/mL (280.76 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years